Glycyrrhetinic acid, a bioactive compound derived from licorice root (Glycyrrhiza glabra), has been investigated for its anti-inflammatory and skin-soothing properties. Its use in the support and treatment of dermatitis is primarily justified by scientific research, albeit with moderate-quality evidence. Glycyrrhetinic acid acts as an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase, which increases the availability of endogenous corticosteroids in the skin, thereby reducing inflammation. Several in vitro and animal studies have demonstrated its ability to suppress pro-inflammatory cytokines and alleviate skin irritation. Small clinical studies and randomized controlled trials have indicated that topical preparations containing glycyrrhetinic acid can reduce erythema, itching, and other symptoms associated with dermatitis and eczema. For example, a double-blind study published in 2003 found that a cream containing 2% glycyrrhetinic acid was more effective than placebo in relieving symptoms of atopic dermatitis. However, large-scale, high-quality human trials are limited, and most available studies are small or preliminary. The use of glycyrrhetinic acid is therefore supported by scientific rationale and early clinical findings, but more robust clinical evidence is needed to firmly establish its efficacy and safety profile for dermatitis treatment.